News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Selexis SA and NKT Therapeutics Inc. Enter Into Research Services Agreement


9/1/2009 11:05:09 AM

GENEVA, Sept. 1 /PRNewswire/ -- Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today that they have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M(TM). The Selexis INTEGRA-D2M(TM) platform enables the rapid isolation of production cell lines concomitant with the selection of lead compounds from libraries of protein variants expressed in Chinese Hamster Ovary (CHO) cells. Utilizing INTEGRA-D2M(TM), protein variant libraries of sizes larger than 10exp3 can be screened to identify lead compounds in less than 9 weeks. The selected CHO-based protein variant expressing clone can then be used directly for cGMP manufacturing.

"We greatly appreciate working with the team at Selexis and utilizing their powerful technology platform," adds Dr. Alem Truneh, Chief Scientific Officer and co-founder of NKT Therapeutics.

About Selexis:

Selexis is a privately held Swiss biotechnology company dedicated to the development of innovative technologies and expert services that enable significant improvements in the time, effort, and costs required to develop and maintain high-performance mammalian cell lines used in the expression of pharmaceutically relevant proteins (i.e. targets, MAbs, rProteins). The company's core intellectual property portfolio is based on the discovery and application of novel DNA based elements that control the dynamic organization of chromatin within all mammalian cells - Selexis Genetic Elements(TM). Selexis has further developed platforms, to include: Selexis SUREtech Vectors(TM), Selexis SUREfection(TM) Selexis SURE Cell Line Development(TM) and Selexis INTEGRA-D2M(TM).

SOURCE Selexis SA

CONTACT: Selexis SA, +41 (0)22 308 93 60, SURE@selexis.com

Web site: http://www.nktrx.com//
http://www.selexis.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES